Clear Cell Sarcomas of the Kidney registered on International Society of Pediatric Oncology (SIOP) 93-01 and SIOP 2001 protocols: A report of the SIOP Renal Tumour Study Group

2013 ◽  
Vol 49 (16) ◽  
pp. 3497-3506 ◽  
Author(s):  
R. Furtwängler ◽  
S.L. Gooskens ◽  
H. van Tinteren ◽  
J. de Kraker ◽  
G. Schleiermacher ◽  
...  
Keyword(s):  
International Society ◽  
Pediatric Oncology ◽  
Clear Cell ◽  
Renal Tumour ◽  
Study Group

Predictive Value of the Pretreatment Extent of Disease System in Hepatoblastoma: Results From the International Society of Pediatric Oncology Liver Tumor Study Group SIOPEL-1 Study

2005 ◽  
Vol 23 (6) ◽  
pp. 1245-1252 ◽  
Author(s):  
Daniël C. Aronson ◽  
J. Marco Schnater ◽  
Chris R. Staalman ◽  
Gerrit J. Weverling ◽  
Jack Plaschkes ◽  
...  
Keyword(s):  
International Society ◽  
Pediatric Oncology ◽  
Predictive Value ◽  
Interobserver Agreement ◽  
Preoperative Staging ◽  
Study Group ◽  
Predictive Values ◽  
Tumor Study ◽  
Staging Systems ◽  
Extent Of Disease

Purpose Preoperative staging (pretreatment extent of disease [PRETEXT]) was developed for the first prospective liver tumor study by the International Society of Pediatric Oncology (SIOPEL-1 study; preoperative chemotherapy and delayed surgery). Study aims were to analyze the accuracy and interobserver agreement of PRETEXT and to compare the predictive impact of three currently used staging systems. Patients and Methods Hepatoblastoma (HB) patients younger than 16 years who underwent surgical resection (128 of 154 patients) were analyzed. The centrally reviewed preoperative staging was compared with postoperative pathology (accuracy) in 91 patients (81%), and the local center staging was compared with the central review (interobserver agreement) in 97 patients (86%), using the agreement beyond change method (weighted κ). The predictive values of the three staging systems were compared in 110 patients (97%) using survival curves and Cox proportional hazard ratio estimates. Results Preoperative PRETEXT staging compared with pathology was correct in 51%, overstaged in 37%, and understaged in 12% of patients (weighted κ = 0.44; 95% CI, 0.26 to 0.62). The weighted κ value of the interobserver agreement was 0.76 (95% CI, 0.64 to 0.88). The Children's Cancer Study Group/Pediatric Oncology Group–based staging system showed no predictive value for survival (P = .516), but the tumor-node-metastasis–based system and PRETEXT system showed good predictive values (P = .0021 and P = .0006, respectively). PRETEXT seemed to be superior in the statistical fit. Conclusion PRETEXT has moderate accuracy with a tendency to overstage patients, shows good interobserver agreement (reproducibility), shows superior predictive value for survival, offers the opportunity to monitor the effect of preoperative therapy, and can also be applied in patients who have not had operations. For comparability reasons, we recommend that all HB patients included in trials also be staged according to PRETEXT.

Trial of Therapy and Prospective Study of Nephroblastoma

PEDIATRICS ◽  
1972 ◽  
Vol 49 (4) ◽  
pp. 638-639
Author(s):  
P. A. Voûte ◽  
J. Lemerle
Keyword(s):  
United States ◽  
Clinical Trial ◽  
Radiation Therapy ◽  
Prospective Study ◽  
International Society ◽  
Pediatric Oncology ◽  
The United States ◽  
Therapeutic Trial ◽  
A Prospective Study

The International Society of Pediatric Oncology (ISPO) is planning a clinical therapeutic trial on nephroblastoma in Europe. Large agreement exists on the treatment of these tumors; the principal modalities are surgery, radiation therapy, and chemotherapy. However, there are some unanswered questions as to the value of different forms of administration of radiation and chemotherapy, which we feel could best be elucidated by a prospective study in the form of a clinical trial. A trial has been going on in the United States for 2 years.

Sign in / Sign up

Export Citation Format

Share Document